Sciegen Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SCIEGEN PHARMS INC, and what generic and branded alternatives to SCIEGEN PHARMS INC drugs are available?
SCIEGEN PHARMS INC has sixty-three approved drugs.
Drugs and US Patents for Sciegen Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sciegen Pharms Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 205519-004 | May 19, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sciegen Pharms Inc | DILTIAZEM HYDROCHLORIDE | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216327-002 | Apr 6, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sciegen Pharms Inc | IRBESARTAN | irbesartan | TABLET;ORAL | 204774-002 | Dec 7, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.